Most longevity interventions are studied using surrogate endpoints — epigenetic clocks, inflammatory markers, mitochondrial gene expression. Here is what those endpoints do and do not establish.
A surrogate endpoint is a biomarker or intermediate outcome that is believed to predict a clinically meaningful outcome — but has not itself been validated as a reliable predictor of that outcome in the context of intervention trials.
The distinction matters enormously in longevity medicine because essentially all longevity supplement claims rest on surrogate endpoints. A compound reduces an epigenetic clock score. Another raises NAD+ levels. A third reduces IL-6. These are all surrogate outcomes. Whether any of them predict reduced mortality or extended healthspan in humans has not been established by the intervention trials themselves.
Epigenetic clocks — Horvath, GrimAge, PhenoAge — are trained on population data to predict biological age and, in some analyses, mortality risk at the population level. They have genuine predictive value in epidemiological settings. What they do not do is provide validated individual-level mortality predictions. More importantly, it has not been demonstrated that interventions which reduce epigenetic clock scores thereby reduce mortality. The clock could shift without affecting underlying aging biology. Two interventions — the TruAge trial of AKG and the TRIIM trial of growth hormone/DHEA/metformin — reported epigenetic clock reductions but had designs too limited to determine whether this reflected true biological age reversal.
Surrogate endpoints are not valueless — they are essential for initial hypothesis testing and mechanistic validation. The question is whether they are used appropriately. A surrogate endpoint showing a plausible mechanistic signal is reason to conduct a larger trial with hard endpoints, not reason to recommend the intervention clinically. In cardiovascular medicine, some surrogate endpoints — LDL cholesterol, blood pressure — have been validated through decades of trials linking endpoint improvements to mortality reductions. In longevity medicine, no surrogate endpoint has yet achieved this level of validation.
Surrogate endpoints in longevity medicine should be treated as hypothesis-generating evidence, not clinical efficacy evidence. When evaluating any longevity claim, the critical question is whether the endpoint used has been validated as a predictor of the outcome of interest — reduced mortality or extended healthspan — in intervention trials. Most longevity surrogate endpoints have not cleared this bar.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.